바이오리액터 시장 규모, 점유율, 예측, 동향 분석 : 유형별, 바이오프로세스별, 유용성별, 규모별, 세포 유형별, 용도별, 사용자별 - 세계 예측(-2031년)

Bioreactors Market Size, Share, Forecast, & Trends Analysis by Type (continuous Stirred Tank, Photobioreactor) Bioprocess (Batch, Continuous) Usability (Reusable, Single-use) Scale (Pilot, Industrial) Cell Type, Application, User-Global Forecast to 2031.

The global bioreactors market is projected to reach $39.96 billion by 2031, at a CAGR of 10.1% from 2024 to 2031.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides insights into the key drivers, restraints, opportunities, and challenges of the bioreactors market. The growth of this market is driven by the expansion of biopharmaceutical plants, the growth of the pharmaceuticals sector, increased R&D expenditures in pharmaceuticals, the rising adoption of biosimilars, and the growing adoption of disposable technologies in the pharmaceutical and biotechnology sectors. However, the complex development & manufacturing processes of biopharmaceuticals and high capital requirements for biopharmaceutical production restrain the market's growth.

Moreover, advancements in bioreactor technologies and the rising adoption of personalized medicines and cell & gene therapies are expected to create market growth opportunities. However, risks associated with extractables and leachables (E&L) in biomanufacturing processes using single-use bioreactors, limitations in scaling up biopharmaceutical processes, the need to standardize designs for single-use bioreactors, and environmental concerns related to the disposal of single-use bioreactors are some of the challenges impacting the market's growth.

Based on product, in 2024, the continuous stirred-tank bioreactors segment is expected to account for the largest share of 31% of the bioreactors market. This segment's large market share can be attributed to technological advancements in continuous stirred-tank bioreactors and their capability to handle higher concentrations of reactants due to their superior heat transfer properties compared to other bioreactors. Additionally, market players are enhancing bioreactor designs to integrate seamlessly with existing flow systems. For instance, in October 2024, Vapourtec Ltd. (U.K.) launched a continuous stirred-tank bioreactor designed for continuous process synthesis, specifically designed to work alongside existing flow-chemistry systems.

Based on bioprocess, in 2024, the batch/fed-batch segment is expected to account for the largest share of the bioreactors market. This segment's large market share can be attributed to the advantages of batch/fed-batch bioprocessing, including high productivity, simplified management of bioprocesses, and reduced risks of contamination. The duration of batch processing is ideal for rapid experimentation and accelerates upstream processes, thereby enhancing overall productivity.

Based on cell type, in 2024, the mammalian cells segment is expected to account for the largest share of the bioreactors market. This segment's large market share can be attributed to the increasing focus on commercial and research bioproduction for complex biomolecules such as monoclonal antibodies and therapeutic proteins. Additionally, the growth in clinical research involving mammalian cells has led to their widespread adoption in single-use bioreactors.

Based on usability, in 2024, the reusable bioreactors segment is expected to account for the larger share of the bioreactors market. This segment's large market share can be attributed to the increase in large-scale manufacturing, where reusable bioreactors are increasingly adopted due to their cost efficiency and suitability for handling high volumes of production. Moreover, the high costs and regulatory restrictions associated with waste disposal drive the increased adoption of reusable bioreactors.

Based on scale, the pilot scale bioreactors (10L-200L) segment is slated to register the highest CAGR in the market. Pilot scale bioreactors are systems that are between the capacity of 10L-200L and include multiple variations and customizations. They find extensive application in the food, pharmaceutical, and cosmetics industries, primarily for testing and refining bioprocesses before full-scale production. The increasing demand for commercial bioproduction drives the adoption of pilot scale bioprocessing, as these bioreactors are crucial in assessing efficiency, scalability, and performance under conditions closely resembling industrial settings.

Based on automation, in 2024, the automated bioreactors segment is expected to account for the larger share of the market. This segment's large market share can be attributed to the benefits offered by automated bioreactors, including enhanced process quality, reduced errors, optimized process control, and cost savings. Automated bioreactors contribute to improved quality and productivity through real-time monitoring and data-rich quality control. They streamline procedures and experiments, ensuring swift detection of deviations in processes.

Based on application, in 2024, the commercial production segment is expected to account for the larger share of the bioreactors market. The commercial production consists of monoclonal antibodies (mAb) production, cell & gene therapy production, vaccine manufacturing, plasma fractionation, and recombinant protein production. This segment's large market share can be attributed to the growing adoption of biopharmaceuticals, favorable regulatory reforms aimed at promoting the adoption of biosimilars, and rising investments in developing gene therapies.

Based on end user, in 2024, the biopharmaceutical manufacturers segment is expected to account for the largest share of the market. Biopharmaceutical companies have witnessed significant growth in recent years due to the increasing demand for biopharmaceuticals, growing incidence of chronic diseases, rising R&D expenditure by pharmaceutical & biotechnology companies, and recent launches of biologics for chronic & rare diseases. Governments of various countries are taking initiatives by making investments and providing grants & funds to biopharmaceutical companies for the manufacture and R&D of biopharmaceuticals, along with several companies that are collaborating to develop sustainable methods for biomanufacturing. These factors contribute to the increased adoption of bioreactors among biopharmaceutical manufacturers, contributing to the segment's large market share.

An in-depth analysis of the geographical scenario of the global bioreactors market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.

In 2024, North America is expected to account for the largest share of 34% of the global bioreactors market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's significant market share can be attributed to the presence of large biopharmaceutical companies, high R&D investments, support from government and regulatory authorities to promote the use of biopharmaceuticals, and initiatives by biopharmaceutical companies to expand their manufacturing capacities.

The key players operating in the global bioreactors market are Thermo Fisher Scientific, Inc. (U.S.), METTLER TOLEDO (U.S.), Merck KGaA (Germany), Eppendorf AG (Germany), Sartorius AG (Germany), Danaher Corporation (U.S.), Donaldson Company, Inc. (U.S.), BBI-Biotech GmbH (Germany), Infors AG (Switzerland), and Pharsol Ltd. (Slovenia).

Scope of the Report:

Bioreactors Market-by Product

• Continuous Stirred Tank Bioreactors
• Airlift Bioreactors
• Fluidized-bed Bioreactors
• Packed-bed Bioreactors
• Photobioreactors
  • Open System Photobioreactors
  • Closed System Photobioreactors
• Membrane Bioreactors

Bioreactors Market-by Bioprocess

• Batch/Fed-batch Bioprocessing
• Continuous Bioprocessing

Bioreactors Market-by Cell Type

• Mammalian Cells
• Bacterial Cells
• Yeast Cells
• Other Cell Types

(Other cell types include plant cells and insect cells)

Bioreactors Market-by Usability

• Reusable Bioreactors
  • Reusable Bioreactors by Material
• Stainless Steel
• Glass
• Single-use Bioreactors

Bioreactors Market-by Scale

• Lab Scale Bioreactors (0.5L-10L)
• Pilot Scale Bioreactors (10L-200L)
• Industrial Scale Bioreactors
  • 200L-500L
  • 500L-1000L
  • Above 1,500L

Bioreactors Market-by Automation

• Manual/Semi-automated Bioreactors
• Automated Bioreactors

Bioreactors Market-by Application

• Commercial Production
  • Monoclonal Antibodies (mAb) Production
  • Cell & Gene Therapy Production
  • Vaccine Manufacturing
  • Plasma Fractionation
  • Recombinant Protein Production
• Developmental, Preclinical, & Clinical

Bioreactors Market-by End User

• Biopharmaceutical Manufacturers
• Research & Development Organizations
• Contract Manufacturing Organizations

Bioreactors Market-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Switzerland
  • Ireland
  • Denmark
  • Belgium
  • Rest of Europe (RoE)
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Rest of APAC (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition & Scope
• 1.2. Market Ecosystem
• 1.3. Currency & Limitations
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumption for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Drivers
  • 4.2.1. Capacity Expansion of Biopharmaceutical Plants
  • 4.2.2. Growing Pharmaceutical Market
  • 4.2.3. Rising Pharmaceutical R&D Expenditures
  • 4.2.4. Rising Adoption of Biosimilars
  • 4.2.5. Growing Adoption of Disposable Technologies in the Pharmaceutical and Biotechnology Industries
• 4.3. Restraints
  • 4.3.1. Complex Development and Manufacturing Process of Biopharmaceuticals
  • 4.3.2. Intensive Capital Requirements for Biopharmaceuticals Production
• 4.4. Opportunities
  • 4.4.1. Technological Advancements in Bioreactor Technologies
  • 4.4.2. Rising Adoption of Personalized Medicines and Cell & Gene Therapies
• 4.5. Challenges
  • 4.5.1. Risk of Extractables and Leachables (E&L) in Biomanufacturing Processes Using Single-use Bioreactors
  • 4.5.2. Process Scale-up Limitations
  • 4.5.3. Need to Standardize Single-use Bioreactor Designs
  • 4.5.4. Environmental Concerns Related to the Disposal of Single-use Bioreactors
• 4.6. Technology Trends/Market Trends
  • 4.6.1. Use of Disposable Processing Equipment for Commercial Production
  • 4.6.2. Rising Focus on Continuous Bioprocessing
  • 4.6.3. Shift Towards Bioprocessing 4.0
  • 4.6.4. Integration of AI in Bioprocessing
• 4.7. Regulatory Scenario
• 4.8. Pricing Analysis
• 4.9. Parent Market Analysis
• 4.10 Porter's Five Forces Analysis

5. Global Bioreactors Market-by Type

• 5.1. Overview
• 5.2. Continuous Stirred-tank Bioreactors
• 5.3. Airlift Bioreactors
• 5.4. Fluidized-bed Bioreactors
• 5.5. Packed-bed Bioreactors
• 5.6. Photobioreactors
  • 5.6.1. Open System Bioreactors
  • 5.6.2. Closed System Bioreactors
• 5.7. Membrane Bioreactors

6. Global Bioreactors Market-by Bioprocess

• 6.1. Overview
• 6.2. Batch/Fed-batch Bioprocessing
• 6.3. Continuous Bioprocessing

7. Global Bioreactors Market-by Cell Type

• 7.1. Overview
• 7.2. Mammalian Cells
• 7.3. Bacterial Cells
• 7.4. Yeast Cells
• 7.5. Other Cell Types

8. Global Bioreactors Market-by Usability

• 8.1. Overview
• 8.2. Reusable Bioreactors
  • 8.2.1. Stainless Steel
  • 8.2.2. Glass
• 8.3. Single-use Bioreactors

9. Global Bioreactors Market-by Scale

• 9.1. Overview
• 9.2. Lab Scale Bioreactors (0.5L-10L)
• 9.3. Pilot Scale Bioreactors (10L-200L)
• 9.4. Industrial Scale Bioreactors
  • 9.4.1. 200L-500L
  • 9.4.2. 500L-1000L
  • 9.4.3. Above 1,500L

10. Global Bioreactors Market-by Application

• 10.1. Overview
• 10.2. Commercial Production
  • 10.2.1. Monoclonal Antibodies (mAb) Production
  • 10.2.2. Cell & Gene Therapy Production
  • 10.2.3. Vaccine Manufacturing
  • 10.2.4. Plasma Fractionation
  • 10.2.5. Recombinant Protein Production
• 10.3. Development, Preclinical, & Clinical

11. Global Bioreactors Market-by End User

• 11.1. Overview
• 11.2. Biopharmaceutical Manufacturers
• 11.3. Research & Development Organizations
• 11.4. Contract Manufacturing Organizations

12. Bioreactors Market-by Geography

• 12.1. Overview
• 12.2. North America
  • 12.2.1. U.S.
  • 12.2.2. Canada
• 12.3. Europe
  • 12.3.1. Germany
  • 12.3.2. France
  • 12.3.3. U.K.
  • 12.3.4. Italy
  • 12.3.5. Spain
  • 12.3.6. Switzerland
  • 12.3.7. Ireland
  • 12.3.8. Denmark
  • 12.3.9. Belgium
  • 12.3.10. Rest of Europe
• 12.4. Asia-Pacific
  • 12.4.1. Japan
  • 12.4.2. China
  • 12.4.3. India
  • 12.4.4. South Korea
  • 12.4.5. Rest of Asia Pacific
• 12.5. Latin America
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Middle East & Africa

13. Competition Analysis

• 13.1. Overview
• 13.2. Key Growth Strategies
• 13.3. Competitive Benchmarking
• 13.4. Competitive Dashboard
  • 13.4.1. Market Leaders
  • 13.4.2. Market Differentiators
  • 13.4.3. Vanguards
  • 13.4.4. Emerging Companies
• 13.5. Market Share Analysis (2023)

14. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

• 14.1. Thermo Fisher Scientific, Inc.
• 14.2. METTLER TOLEDO
• 14.3. Merck KGaA
• 14.4. Eppendorf AG
• 14.5. Sartorius AG
• 14.6. Danaher Corporation
• 14.7. Donaldson Company, Inc.
• 14.8. BBI-Biotech GmbH
• 14.9. Infors AG
• 14.10. Pharsol Ltd.
• 14.11. Other Companies

(Note: SWOT analysis of the top 5 companies will be provided.)

15. Appendix

• 15.1. Available Customization
• 15.2. Related Reports